Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Vaduganathan, R. Harrington, G. Stone, P. Steg, C. Gibson, C. Hamm, M. Price, J. Prats, E. Deliargyris, K. Mahaffey, H. White, Deepak Bhatt (2016)
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX TrialCirculation. Cardiovascular Interventions, 9
M. Mohammad, P. Andell, Matthias Götberg, F. Scherstén, S. Koul, D. Erlinge (2016)
REAL-LIFE ASSESSMENT OF CANGRELOR P2Y12-INHIBITION IN PATIENTS WITH ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTIONJournal of the American College of Cardiology, 67
Kush Agrawal, Deepak Bhatt (2013)
Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?Nature Reviews Cardiology, 10
S. Rao, Kristi O'Grady, K. Pieper, C. Granger, L. Newby, F. Werf, K. Mahaffey, R. Califf, R. Harrington (2005)
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.The American journal of cardiology, 96 9
TY Wang, A Gutierrez, ED Peterson (2011)
Percutaneous coronary intervention in the elderlyNat Rev Cardiol., 8
M. Cavender, Deepak Bhatt, G. Stone, P. Steg, C. Gibson, C. Hamm, M. Price, J. Prats, Tiepu Liu, E. Deliargyris, K. Mahaffey, H. White, R. Harrington (2015)
CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIXJournal of the American College of Cardiology, 65
Mark Petrie, Eva Swahn, Christiaan Vrints (2011)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
H. White, Deepak Bhatt, C. Gibson, C. Hamm, K. Mahaffey, M. Price, P. Steg, G. Stone, B. Cortese, M. Wilensky, E. Deliargyris, Tiepu Liu, J. Prats, R. Harrington (2015)
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).JACC. Cardiovascular interventions, 8 3
B. Dean, Hsing-Ting Yu, J. Bae, S. Fiske, E. Meadows, Y. Xiong, M. Emons (2010)
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 67 17
P. Ecurrent, E. Rial (2001)
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont, Abstr Act (2009)
Genetic determinants of response to clopidogrel and cardiovascular events.The New England journal of medicine, 360 4
P. Ho, E. Peterson, Li Wang, D. Magid, S. Fihn, G. Larsen, R. Jesse, J. Rumsfeld (2008)
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.JAMA, 299 5
M. O’Donoghue, Deepak Bhatt, G. Stone, P. Steg, C. Gibson, C. Hamm, M. Price, J. Prats, Tiepu Liu, E. Deliargyris, K. Mahaffey, H. White, R. Harrington (2016)
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
M. Cavender, Deepak Bhatt, G. Stone, H. White, P. Steg, C. Gibson, C. Hamm, M. Price, S. Leonardi, J. Prats, E. Deliargyris, K. Mahaffey, R. Harrington (2016)
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple DefinitionsCirculation, 134
SR Mehta, S Yusuf, RJ Peters (2001)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet., 358
P. Steg, Deepak Bhatt, C. Hamm, G. Stone, F. Investigators (2013)
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level dataThe Lancet, 382
H. Krumholz, J. Herrin, Lauren Miller, E. Drye, Shari Ling, L. Han, M. Rapp, E. Bradley, B. Nallamothu, W. Nsa, D. Bratzler, J. Curtis (2011)
Improvements in Door-to-Balloon Time in the United States, 2005 to 2010Circulation, 124
H. Dauerman, Deepak Bhatt, D. Gretler, Patricia French, S. Smyth, R. Becker (2010)
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients.American heart journal, 159 4
Deepak Bhatt (2009)
Antiplatelet therapy: Ticagrelor in ACS—what does PLATO teach us?Nature Reviews Cardiology, 6
J. Gutierrez, R. Harrington, J. Blankenship, G. Stone, P. Steg, C. Gibson, C. Hamm, M. Price, P. Généreux, J. Prats, E. Deliargyris, K. Mahaffey, H. White, Deepak Bhatt, D. Bhatt, G. Stone, K. Mahaffey, C. Gibson, P. Steg, C. Hamm, M. Price, S. Leonardi, D. Gallup, E. Bramucci, P. Radke, P. Widimsky, F. Toušek, J. Tauth, D. Spriggs, B. McLaurin, D. Angiolillo, P. Généreux, T. Liu, J. Prats, M. Todd, S. Skerjanec, H. White, R. Harrington (2015)
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIXEuropean Heart Journal, 37
S. Walsh, K. McAuley, P. Johnston (2007)
Percutaneous Coronary Intervention in the ElderlyThe Ulster Medical Journal, 76
Francesco Franchi, F. Rollini, J. Cho, Mona Bhatti, C. DeGroat, Elisabetta Ferrante, E. Dunn, A. Nanavati, E. Carraway, S. Suryadevara, Martin Zenni, Luis Guzmán, T. Bass, D. Angiolillo (2015)
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.JACC. Cardiovascular interventions, 8 11
W. Akers, Jennifer Oh, J. Oestreich, S. Ferraris, Mary Wethington, S. Steinhubl (2010)
Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor AntagonistThe Journal of Clinical Pharmacology, 50
P. Poole‐Wilson (2008)
Global differences in the outcome of heart failure: implications for clinical practice.Journal of the American College of Cardiology, 52 20
Deepak Bhatt, J. Hulot, D. Moliterno, R. Harrington (2014)
Antiplatelet and Anticoagulation Therapy for Acute Coronary SyndromesCirculation Research, 114
M. Sabatine, C. Cannon, C. Gibson, J. López-Sendón, G. Montalescot, P. Théroux, M. Claeys, F. Cools, K. Hill, A. Skene, C. Mccabe, E. Braunwald (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.The New England journal of medicine, 352 12
Deepak Bhatt, E. Topol (2000)
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.JAMA, 284 12
Eva‐Luise Hobl, B. Reiter, C. Schoergenhofer, M. Schwameis, U. Derhaschnig, I. Lang, T. Stimpfl, B. Jilma (2015)
Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteersClinical Research in Cardiology, 105
Pei-Hsiu Huang, K. Croce, Deepak Bhatt, F. Resnic (2012)
Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation.Critical pathways in cardiology, 11 4
M. Roffi, C. Patrono, J. Collet, Christian Mueller, M. Valgimigli, F. Andreotti, Jeroen Bax, M. Borger, C. Brotons, Derek Chew, B. Gencer, G. Hasenfuß, K. Kjeldsen, P. Lancellotti, U. Landmesser, J. Mehilli, D. Mukherjee, R. Storey, S. Windecker (2011)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).European heart journal, 37 3
P. Vlaar, R. Lennon, C. Rihal, Mandeep Singh, H. Ting, J. Bresnahan, D. Holmes (2008)
Drug-eluting stents in octogenarians: early and intermediate outcome.American heart journal, 155 4
W. Batchelor, K. Anstrom, L. Muhlbaier, R. Grosswald, W. Weintraub, W. O’Neill, E. Peterson (2000)
Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration.Journal of the American College of Cardiology, 36 3
J. Eikelboom, S. Mehta, Sonia Anand, C. Xie, K. Fox, S. Yusuf (2006)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 114
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
Antonio Gutierrez, Deepak Bhatt (2014)
Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention.European heart journal, 35 36
K. Fox, S. Mehta, R. Peters, F. Zhao, N. Lakkis, B. Gersh, S. Yusuf (2004)
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) TrialCirculation, 110
D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K. Theodoropoulos, G. Makris, N. Koutsogiannis, A. Damelou, Grigorios Tsigkas, P. Davlouros, G. Hahalis (2012)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 5
P. Widimsky, Z. Motovska, S. Simek, P. Kala, R. Pudil, F. Holm, R. Petr, D. Bílková, H. Skalická, P. Kuchynka, M. Poloczek, R. Miklik, M. Malý, M. Aschermann (2008)
Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8European Heart Journal, 29
Deepak Bhatt (2007)
Intensifying platelet inhibition--navigating between Scylla and Charybdis.The New England journal of medicine, 357 20
F. Rollini, Francesco Franchi, D. Angiolillo (2016)
Switching P2Y12-receptor inhibitors in patients with coronary artery diseaseNature Reviews Cardiology, 13
W. Fan, S. Plent, J. Prats, E. Deliargyris (2016)
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.The American journal of cardiology, 117 9
G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, J. Tanguay, J. Berg, Debra Miller, T. Costigan, J. Goedicke, J. Silvain, P. Angioli, J. Legutko, Margit Niethammer, Z. Motovska, J. Jakubowski, G. Cayla, L. Visconti, E. Vicaut, P. Widimsky (2013)
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.The New England journal of medicine, 369 11
S. Rao, Zoltan Turi, Zoltan Turi, S. Wong, S. Brener, G. Stone (2013)
Radial versus femoral access.Journal of the American College of Cardiology, 62 17 Suppl
E. Antman, D. Anbe, P. Armstrong, Eric Bates, L. Green, M. Hand, J. Hochman, H. Krumholz, F. Kushner, G. Lamas, C. Mullany, J. Ornato, D. Pearle, M. Sloan, Sidney Smith (2004)
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients WiThe Canadian journal of cardiology, 20 10
S. Mehta (2013)
Cangrelor: a new CHAMPION for percutaneous coronary interventionThe Lancet, 382
M. Roizen (2007)
Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled TrialsYearbook of Anesthesiology and Pain Management, 2007
Deepak Bhatt, A. Lincoff, C. Gibson, G. Stone, S. McNulty, G. Montalescot, N. Kleiman, S. Goodman, H. White, K. Mahaffey, C. Pollack, S. Manoukian, P. Widimsky, D. Chew, F. Cura, I. Manukov, F. Toušek, M. Jafar, Jaspal Arneja, S. Skerjanec, R. Harrington (2009)
Intravenous platelet blockade with cangrelor during PCI.The New England journal of medicine, 361 24
J. Collet, J. Hulot, A. Pena, E. Villard, J. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, G. Montalescot (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 373
PG Steg, SK James, D Atar (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC)Eur Heart J., 33
D. Schneider, N. Seecheran, Syed Raza, F. Keating, Prospero Gogo (2015)
Pharmacodynamic effects during the transition between cangrelor and prasugrelCoronary Artery Disease, 26
D. Capodanno, D. Angiolillo (2015)
Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era: Review of the Evidence and Practice GuidelinesCirculation: Cardiovascular Interventions, 8
H. White, D. Chew, H. Dauerman, K. Mahaffey, C. Gibson, G. Stone, L. Gruberg, R. Harrington, Deepak Bhatt (2012)
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.American heart journal, 163 2
D. Angiolillo, M. Firstenberg, M. Price, P. Tummala, M. Hutyra, I. Welsby, Michele Voeltz, H. Chandna, Chand Ramaiah, M. Brtko, L. Cannon, C. Dyke, Tiepu Liu, G. Montalescot, S. Manoukian, J. Prats, E. Topol (2012)
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.JAMA, 307 3
S. Leonardi, K. Mahaffey, H. White, C. Gibson, G. Stone, G. Steg, C. Hamm, M. Price, M. Todd, M. Dietrich, D. Gallup, Tiepu Liu, S. Skerjanec, R. Harrington, Deepak Bhatt (2012)
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.American heart journal, 163 5
D. Taubert, H. Bouman, J. Werkum (2009)
Cytochrome P-450 polymorphisms and response to clopidogrel.The New England journal of medicine, 360 21
Deepak Bhatt (2009)
Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?JAMA, 302 8
Deepak Bhatt, M. Roe, E. Peterson, Yun Li, A. Chen, R. Harrington, A. Greenbaum, P. Berger, C. Cannon, D. Cohen, C. Gibson, J. Saucedo, N. Kleiman, J. Hochman, W. Boden, R. Brindis, W. Peacock, Sidney Smith, C. Pollack, W. Gibier, E. Ohman (2004)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement InitiativeJAMA, 292
A. Jacobs, F. Kushner, S. Ettinger, R. Guyton, Jeffrey Anderson, E. Ohman, N. Albert, E. Antman, D. Arnett, M. Bertolet, Deepak Bhatt, R. Brindis, M. Creager, D. DeMets, K. Dickersin, G. Fonarow, R. Gibbons, J. Halperin, J. Hochman, M. Koster, S. Normand, Eduardo Ortiz, E. Peterson, William Roach, R. Sacco, Sidney Smith, W. Stevenson, G. Tomaselli, C. Yancy, W. Zoghbi, J. Harold, Yulei He, P. Mangu, A. Qaseem, M. Sayre, M. Somerfield (2013)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation, 127 4
Eva‐Luise Hobl, T. Stimpfl, J. Ebner, C. Schoergenhofer, U. Derhaschnig, R. Sunder-Plassmann, P. Jilma-Stohlawetz, C. Mannhalter, M. Posch, B. Jilma (2014)
Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.Journal of the American College of Cardiology, 63 7
P. O'Gara, F. Kushner, D. Ascheim, D. Casey, M. Chung, J. Lemos, S. Ettinger, J. Fang, F. Fesmire, B. Franklin, C. Granger, H. Krumholz, Jane Linderbaum, D. Morrow, L. Newby, J. Ornato, N. Ou, M. Radford, J. Tamis-Holland, C. Tommaso, C. Tracy, Y. Woo, David Zhao (2013)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 61 4
J. Berger, Deepak Bhatt, C. Cannon, Zhengming Chen, Lixin Jiang, J. Jones, S. Mehta, M. Sabatine, S. Steinhubl, E. Topol, P. Berger (2009)
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.Journal of the American College of Cardiology, 54 21
E. Amsterdam, N. Wenger, R. Brindis, D. Casey, T. Ganiats, D. Holmes, A. Jaffe, H. Jneid, R. Kelly, M. Kontos, G. Levine, P. Liebson, D. Mukherjee, E. Peterson, M. Sabatine, R. Smalling, Susan Zieman (2014)
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 64 24
P. Généreux, G. Stone, R. Harrington, C. Gibson, P. Steg, S. Brener, D. Angiolillo, M. Price, J. Prats, L. Lasalle, Tiepu Liu, M. Todd, S. Skerjanec, C. Hamm, K. Mahaffey, H. White, Deepak Bhatt (2014)
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).Journal of the American College of Cardiology, 63 7
Deepak Bhatt, G. Stone, K. Mahaffey, C. Gibson, P. Steg, C. Hamm, M. Price, S. Leonardi, D. Gallup, E. Bramucci, P. Radke, P. Widimsky, F. Toušek, J. Tauth, D. Spriggs, B. McLaurin, D. Angiolillo, P. Généreux, Tiepu Liu, J. Prats, M. Todd, S. Skerjanec, H. White, R. Harrington (2013)
Effect of platelet inhibition with cangrelor during PCI on ischemic events.The New England journal of medicine, 368 14
D. Alexopoulos, Deepak Bhatt, C. Hamm, P. Steg, G. Stone (2015)
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.American heart journal, 170 1
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
M. Sabatine, C. Cannon, C. Gibson, J. López-Sendón, G. Montalescot, P. Théroux, B. Lewis, S. Murphy, C. Mccabe, E. Braunwald (2005)
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.JAMA, 294 10
Caroline Milton, Prashanthan Sanders, P. Steele (2001)
For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt
D. Schneider, Z. Agarwal, N. Seecheran, F. Keating, Prospero Gogo (2014)
Pharmacodynamic effects during the transition between cangrelor and ticagrelor.JACC. Cardiovascular interventions, 7 4
D. Angiolillo, D. Schneider, Deepak Bhatt, W. French, M. Price, J. Saucedo, T. Shaburishvili, K. Huber, J. Prats, Tiepu Liu, R. Harrington, R. Becker (2012)
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trialsJournal of Thrombosis and Thrombolysis, 34
Won Kim (2017)
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.Journal of the American College of Cardiology, 69 2
Tracy Wang, D. Angiolillo, M. Cushman, M. Sabatine, P. Bray, S. Smyth, H. Dauerman, Patricia French, R. Becker (2012)
Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.Journal of the American College of Cardiology, 59 10
Jeremiah Depta, Deepak Bhatt (2015)
New approaches to inhibiting platelets and coagulation.Annual review of pharmacology and toxicology, 55
S. Steinhubl, Peter Berger, J. III, Edward Fry, A. Delago, C. Wilmer, E. Topol (2002)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.JAMA, 288 19
S. Brener, Ecaterina Cristea, A. Kirtane, M. McEntegart, Ke Xu, R. Mehran, G. Stone (2013)
Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes.JACC. Cardiovascular interventions, 6 1
P. Steg, Stefan James, D. Atar, Luigi Badano, C. Blömstrom-Lundqvist, M. Borger, Carlo Mario, Kenneth Dickstein, Gregory Ducrocq, Francisco Fernández-Avilés, A. Gershlick, Pantaleo Giannuzzi, S. Halvorsen, Kurt Huber, Peter Juni, Adnan Kastrati, Juhani Knuuti, Mattie Lenzen, K. Mahaffey, M. Valgimigli, Arnoud Hof, Petr Widimsky, D. Zahger (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.European heart journal, 33 20
J. O'shea, R. Calif (2000)
Inter-regional differences in acute coronary syndrome trials.European heart journal, 21 17
Arman Qamar, Deepak Bhatt (2016)
Current status of data on cangrelor.Pharmacology & therapeutics, 159
Eva‐Luise Hobl, B. Reiter, C. Schoergenhofer, M. Schwameis, U. Derhaschnig, J. Kubica, T. Stimpfl, B. Jilma (2016)
Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteersEuropean Journal of Clinical Investigation, 46
(2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
D. Angiolillo, Deepak Bhatt, P. Steg, G. Stone, H. White, C. Gibson, C. Hamm, M. Price, J. Prats, Tiepu Liu, K. Mahaffey, R. Harrington (2015)
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsJournal of Thrombosis and Thrombolysis, 40
R. Harrington, G. Stone, S. McNulty, H. White, A. Lincoff, C. Gibson, C. Pollack, G. Montalescot, K. Mahaffey, N. Kleiman, S. Goodman, M. Amine, D. Angiolillo, R. Becker, D. Chew, W. French, F. Leisch, K. Parikh, S. Skerjanec, Deepak Bhatt (2009)
Platelet inhibition with cangrelor in patients undergoing PCI.The New England journal of medicine, 361 24
Patrick Lee, K. Alexander, B. Hammill, S. Pasquali, E. Peterson (2001)
Representation of elderly persons and women in published randomized trials of acute coronary syndromes.JAMA, 286 6
L. Součková, R. Opatrilova, P. Suk, I. Čundrle, M. Pavlík, V. Zvonícek, O. Hlinomaz, V. Šrámek (2012)
Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)European Journal of Clinical Pharmacology, 69
Thrombotic events such as myocardial infarction or stent thrombosis are the major cause of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI). While current antiplatelet agents, anticoagulants, and PCI techniques have reduced the risk of thrombotic events in PCI-treated patients, a considerable hazard still remains. Cangrelor is an intravenous P2Y12 receptor antagonist that provides a rapid onset and maximal platelet inhibition, which is quickly reversible. In the large-scale CHAMPION PHOENIX trial, cangrelor was shown to reduce ischemic events significantly, including myocardial infarction and stent thrombosis, without increasing the risk of severe bleeding across the full spectrum of patients undergoing PCI, with substantial benefits in all patient subgroups examined. The pharmacologic profile of cangrelor makes it a valuable addition to the armamentarium of physicians providing care to a broad range of patients with coronary artery disease. Cangrelor is currently approved for reducing thrombotic events in patients undergoing PCI who have not been pretreated with a P2Y12 receptor inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor. Future studies are needed to determine the role of cangrelor in other clinical settings, such as upstream therapy in ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and as a bridge to coronary artery bypass graft (CABG) or other non-cardiac surgeries in patients who require ongoing adenosine diphosphate receptor blockade.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 27, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.